|
|
|
|
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances The Effectiveness Of Standard Cancer Chemotherap
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances The Effectiveness Of Standard Chemotherapy In Animal Models Medical Medical Medical Worldwide Search / Oncology hip Funny Useful Websites details of 26,000 UK specialists...
|
|
|
Work Status Changes More Common Among Women Receiving Chemotherapy For Breast Cancer, Study Says
Status Changes More Common Among Women Receiving Chemotherapy For Breast , Study Says Medical Medical Medical Worldwide Search / Oncology hip Funny Useful Websites details of 26,000 UK specialists medical software Ask a Doctor and...
|
|
|
Saladax Biomedical Inks Pact with Stockholm's Karolinska University Hospital
Saladax Biomedical, Inc., developer of the Personalized Chemotherapy Management (PCM) line of tests to measure blood levels of cancer drugs, has signed an agreement with the Karolinska University Hospital, of Stockholm.In a...
|
|
|
Work Status Changes More Common Among Women Receiving Chemotherapy For Breast Cancer, Study Says
Women with breast cancer who receive chemotherapy appear more likely than those treated with radiation therapy to experience a major change in work status, according to a published in the journal Cancer, reports.For the ,...
|
|
|
Struggling with cancer - and personal questions from the government
Struggling through what might be the last year of her life, Laura DeLong Smith heard some good news in late May.A counselor from the American Cancer Society told her she qualified for a Social Security program that gives monthly...
|
|
|
Struggling with cancer - and government forms
Struggling through what might be the last year of her life, Laura DeLong Smith heard some good news in late May.A counselor from the American Cancer Society told her she qualified for a Social Security program that gives monthly...
|
|
|
TopAbstracts in Acute Lymphoblastic Leukemia (ALL) 07/01/2009
Recent news - Acute Lymphoblastic Leukemia (ALL) Treating childhood acute lymphoblastic leukemia without cranial irradiation- (N Engl J Med) Personalised Chemotherapy Can Replace Cranial Radiation in Paediatric ALL- (DGNews)...
|
|
|
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin...
|
|
|
New Trojan Horse Treatment Sneaks Into, Sabotages Cancer Cells
Chemotherapy destroys cancer cells, but it also kills healthy cells.In addition, cancer cells left behind after treatment can develop resistance to therapy, rendering follow-up treatment ineffective. But a new type of ...
|
|
|
Induction Therapy with Bortezomib Plus Chemotherapy Overcomes Poor Cytogenetics in Young Multiple Myeloma Pati
Induction Therapy with Bortezomib Plus Chemotherapy Overcomes Poor Cytogenetics Induction Therapy with Bortezomib Plus Chemotherapy Overcomes Poor Cytogenetics in Young Multiple Myeloma Pati.
|
|
|
[Breast Cancer] Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutatio
From the Family Cancer Clinic, Departments of Medical Oncology, Oncological Surgery, and Clinical Genetics Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.* To whom correspondence should be addressed. E...
|
|
|
[Head and Neck Cancer] Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal C
From the Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Statistics, American College of Radiology, Philadelphia, PA; The University of Texas M.Anderson Cancer Center, Houston, TX; Image-Guided Therapy...
|
|
|
Calixa Therapeutics Announces Initiation Of Phase 2 Clinical Trial Of Its Antibiotic, CXA-101, In Patients Wit
Calixa Therapeutics Inc.today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in...
|
|
|
[Correspondence] African American Women Who Receive Primary Anthracycline- and Taxane-Based Chemotherapy for T
This Article Google Scholar Social Bookmarking Ani Balmanoukian1, Zhe Zhang1, Stacie Jeter1, Shannon Slater1, Deborah K.Armstrong1, Leisha A. Emens1, John H. Fetting1, Antonio C. Wolff1, Nancy E. Davidson2, Lisa Jacobs3, Julie...
|
|
|
Glossary of cancer treatment terms
Benign: A growth which is not a cancer, and not a pre-cancer.Being benign is not a guarantee that a growth will not cause problems. For example: in a closed space, such as inside the skull, a benign growth can still cause...
|
|
|
Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus
- Guidelines Specify that Validated Molecular Assays Should be Considered as an Adjunct to Standard Measures in Helping Determine Chemotherapy Benefit - GENEVA, and REDWOOD CITY, Calif., June 26 /PRNewswire-FirstCall/ -- Genomic Health...
|
|
|
Facing cancer without fear
Snoqualmie Valley Record Reporter Lisa Newell is nervous as she signs in at Seattle Cancer Care Alliance.The nurse at the check-in desk clips a plastic identification bracelet onto her wrist, and Newell sits down in a simple chair...
|
|
|
Saladax Biomedical, Inc. Signs Agreement with Stockholms Karolinska University Hospital
- Saladax Biomedical, Inc.(www.saladax.com), developer of the Personalized Chemotherapy Management (PCM) line of tests to measure blood levels of cancer drugs, has signed an agreement with the Karolinska University Hospital,...
|
|
|
Saladax Biomedical, Inc. Signs Agreement with Stockholms Karolinska University Hospital
Saladax Biomedical, Inc.(www.saladax.com), developer of the Personalized Chemotherapy Management (PCM) line of tests to measure blood levels of cancer drugs, has signed an agreement with the Karolinska University Hospital, of...
|
|
|
Chemotherapy-Related Cardiac Toxicity Requires Mor
Orlando, Fla.-Modern chemotherapy often can cure cancer, but at a significant cost to the heart, according to a growing body of data showing life-long cardiomyopathy in many cancer survivors.Chemotherapy-related...
|
|
|
New hope for cancer patient
Boulder City woman 'so appreciative' of donations to fund treatment By JACK BULAVSKY SPECIAL TO VIEW Jerry henkel/viewAnn Zapolski sits beneath a tree in Broadbent Park, June 19.Organizers of a barbecue fundraiser at the park July 11 hope...
|
|
|
Primary Endpoint Achieved in Phase III Clinical Trial of Epogin in Chemotherapy Induced Anemia
(Tokyo) - Chugai Pharmaceutical Co., Ltd.('Chugai') [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama] announced today that Phase III study of the recombinant human erythropoietin 'Epogin Injection' [generic name: epoetin beta ...
|
|
|
Primary Endpoint Achieved in Phase III Clinical Trial of Epogin in Chemotherapy Induced Anemia
- Chugai Pharmaceutical Co., Ltd.('Chugai') [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama] announced today that Phase III study of the recombinant human erythropoietin 'Epogin In the double-blind study, patients with...
|
|
|
Primary Endpoint Achieved in Phase III Clinical Trial of Epogin in Chemotherapy Induced Anemia
- Chugai Pharmaceutical Co., Ltd.('Chugai') [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama] announced today that Phase III study of the recombinant human erythropoietin 'Epogin Injection' [generic name: epoetin beta (recombinant)...
|
|
|
Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients wit
SAN DIEGO, June 30 /PRNewswire/ -- Calixa Therapeutics Inc.today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral...
|
